Create a comprehensive SOAP note for a 62-year-old female presenting with shortness of breath, fatigue, and bilateral ankle swelling, focusing on heart failure, including relevant contributory history, differential diagnoses, diagnostic work‑up, evidence‑based treatment plan, follow‑up, and patient education.

SOAP Note: Heart Failure Presentation

PATIENT: Linda
AGE: 62-year-old female
INSTITUTION: [INSTITUTION]
PROVIDER: [PROVIDER]
DATE: [DATE]
COURSE: NUR 677: Primary Care Chronic Conditions Across the Lifespan

---

SUBJECTIVE

Patient Data

• Age: 62 years old
• Gender: Female
• Race/Ethnicity: [To be documented]
• Source and reliability: Patient is a reliable historian

Chief Complaint (CC)

"I've been having trouble breathing and I'm so tired all the time. My ankles have been swelling up lately."

History of Present Illness (HPI) - OLDCART

Onset: Symptoms began approximately 3-4 weeks ago with gradual worsening over the past week. 1

Location: Shortness of breath is generalized; ankle swelling is bilateral and symmetric. 1

Duration: Dyspnea is now present with minimal exertion such as walking from room to room; ankle swelling is persistent throughout the day and worsens by evening. 2

Character: Patient describes profound fatigue that limits her ability to complete activities of daily living, progressive dyspnea on exertion, and bilateral pitting edema of the ankles. 2 She reports needing to sleep propped up on 3 pillows at night (orthopnea) and waking up gasping for air 2-3 times per night (paroxysmal nocturnal dyspnea). 1

Aggravating factors: Symptoms worsen with physical activity, lying flat, and by end of day. 2

Relieving factors: Sitting upright provides some relief of dyspnea; elevating legs reduces ankle swelling temporarily. 1

Timing: Dyspnea is now present at rest; nocturnal symptoms occur 2-3 times nightly. 2, 1

Associated symptoms: Patient reports sudden weight gain of 8 pounds over the past 2 weeks, decreased appetite, occasional nausea, persistent dry cough (especially at night), and palpitations. 2 She denies chest pain, hemoptysis, syncope, or fever. 1

Past Medical History (PMH)

• Hypertension (diagnosed 15 years ago, poorly controlled on single agent)
• Type 2 Diabetes Mellitus (diagnosed 10 years ago, HbA1c 8.2% at last check)
• Hyperlipidemia (diagnosed 8 years ago)
• Obesity (BMI 34)
• Coronary artery disease (positive stress test 2 years ago, managed medically, no revascularization)
• Osteoarthritis (knees, takes NSAIDs regularly)

Surgical History (SxH)

• Cholecystectomy (age 45)
• No cardiac surgeries

Family History (FH)

• Father: Deceased at age 58 from myocardial infarction
• Mother: Living, age 85, history of hypertension and heart failure
• Siblings: One brother with coronary artery disease, status post CABG at age 60

Social History

• Occupation: Retired office manager
• Living situation: Lives with husband in single-story home
• Tobacco: Former smoker, 20 pack-year history, quit 10 years ago
• Alcohol: Occasional wine with dinner, 2-3 glasses per week
• Exercise: Sedentary lifestyle due to knee pain and increasing fatigue
• Diet: High sodium intake, frequent consumption of processed foods and restaurant meals
• Stress: Moderate stress related to caring for elderly mother

Health Maintenance

• Immunizations: Influenza vaccine current (10/2024), COVID-19 booster (09/2024), Pneumovax (2020), Tdap (2022)
• Last physical exam: 18 months ago
• Mammogram: Current (6 months ago, normal)
• Colonoscopy: Due (last performed age 52)

Allergies

• NKDA
• Sulfa drugs: Rash

Current Medications

• Lisinopril 10 mg daily (for hypertension)
• Metformin 1000 mg twice daily (for diabetes)
• Atorvastatin 20 mg daily (for hyperlipidemia)
• Ibuprofen 600 mg three times daily as needed (for knee pain - patient takes regularly)
• Aspirin 81 mg daily

Review of Systems (ROS)

General: Reports profound fatigue, sudden weight gain of 8 pounds over 2 weeks, decreased appetite, and generalized weakness. 2 Denies fever, chills, or unintentional weight loss prior to recent gain.

Cardiovascular: Reports dyspnea on exertion progressing to dyspnea at rest, orthopnea requiring 3 pillows, paroxysmal nocturnal dyspnea 2-3 times nightly, bilateral ankle edema, and palpitations. 1 Denies chest pain, syncope, or claudication.

Respiratory: Reports dry cough worse at night, dyspnea with minimal exertion, and inability to lie flat. 2 Denies hemoptysis, wheezing, or pleuritic chest pain.

Gastrointestinal: Reports decreased appetite, occasional nausea, and abdominal bloating. 2 Denies vomiting, diarrhea, melena, or hematochezia.

Genitourinary: Reports decreased urine output over past week. Denies dysuria, hematuria, or urinary frequency.

Musculoskeletal: Reports chronic bilateral knee pain managed with NSAIDs. Denies new joint pain or muscle weakness beyond generalized fatigue.

Neurological: Denies headache, dizziness, syncope, numbness, tingling, weakness, or confusion.

Psychiatric: Reports mild anxiety related to worsening symptoms. Denies depression or suicidal ideation.

---

OBJECTIVE

Vital Signs

• BP: 158/94 mmHg (right arm, seated)
• HR: 98 bpm (regular)
• RR: 22 breaths per minute
• Temp: 98.4°F (oral)
• SpO2: 93% on room air
• Height: 64 inches
• Weight: 198 lbs (patient reports usual weight 190 lbs)
• BMI: 34.0

Physical Examination

General: 62-year-old female who appears mildly dyspneic at rest, sitting upright in chair. Patient is alert and oriented x4, appropriately dressed and well-groomed. Appears uncomfortable and fatigued. Patient is a reliable historian. 1

HEENT:

• Head: Normocephalic, atraumatic
• Eyes: Conjunctiva pink, sclera white, pupils equal round and reactive to light 3mm bilaterally, extraocular movements intact
• Ears: Bilateral tympanic membranes intact with good cone of light, canals clear
• Nose: Mucosa pink, septum midline, no sinus tenderness
• Oropharynx: Oral mucosa pink and moist, dentition fair with some missing molars, tongue midline, no pharyngeal erythema or exudate

Neck: Supple, jugular venous distension present at 45 degrees measuring 10 cm above sternal angle. 1 No thyromegaly or lymphadenopathy. Trachea midline.

Cardiovascular: Regular rate and rhythm, S1 and S2 present, S3 gallop audible at apex. 3 No murmurs or rubs appreciated. Point of maximal impulse displaced laterally to anterior axillary line at 6th intercostal space, suggesting cardiomegaly. 3 Distal pulses +2 bilaterally and symmetric. Bilateral pitting edema +2 to mid-calf level. 1

Respiratory: Respiratory rate elevated at 22 breaths per minute with mild increased work of breathing. Bibasilar crackles present in lower one-third of lung fields bilaterally. 3 No wheezes or rhonchi. Chest expansion symmetric. Dullness to percussion at bilateral lung bases suggesting small pleural effusions. 3

Abdomen: Soft, mildly distended, non-tender. Normoactive bowel sounds in all four quadrants. Liver edge palpable 2 cm below right costal margin, smooth and non-tender, suggesting hepatomegaly. 3 Hepatojugular reflux positive (sustained elevation of JVP with abdominal pressure). 3 No splenomegaly or masses. Mild ascites appreciated with shifting dullness.

Musculoskeletal: Bilateral knee crepitus with range of motion, no effusion or erythema. Gait not assessed due to dyspnea. No clubbing of digits. 1

Neurological: Alert and oriented to person, place, time, and situation. Cranial nerves II-XII grossly intact. Motor strength 5/5 in upper extremities, 4/5 in lower extremities (limited by fatigue). Sensation intact to light touch. Deep tendon reflexes +2 bilaterally and symmetric.

Integumentary: Skin warm and dry. No cyanosis, jaundice, or rashes. Bilateral lower extremity pitting edema as noted above.

Psychiatric: Mood appears anxious but appropriate to situation. Affect congruent. Cooperative and engaged in interview.

---

ASSESSMENT

Primary Diagnosis

1. Acute Decompensated Chronic Heart Failure with Reduced Ejection Fraction (HFrEF), NYHA Class III-IV (ICD-10: I50.23 - Acute on chronic systolic heart failure)

Clinical reasoning: This 62-year-old female presents with the classic triad of dyspnea, fatigue, and bilateral ankle edema consistent with heart failure. 1 The presence of orthopnea, paroxysmal nocturnal dyspnea, S3 gallop, jugular venous distension, positive hepatojugular reflux, bibasilar crackles, hepatomegaly, and bilateral pitting edema constitute multiple major Framingham criteria for heart failure diagnosis. 3 Her profound fatigue is more reliable than dyspnea as an indicator of advanced functional class. 2 The sudden 8-pound weight gain over 2 weeks indicates acute decompensation. 2

Contributory factors: Multiple risk factors are present including long-standing poorly controlled hypertension, type 2 diabetes mellitus, coronary artery disease, obesity, hyperlipidemia, positive family history (mother with heart failure, father with early MI), and former smoking history. 4, 5 Critically, her regular use of NSAIDs (ibuprofen) is a major exacerbating factor as NSAIDs cause sodium retention, increase blood pressure, and directly worsen heart failure. 3, 6 Her high sodium diet and sedentary lifestyle are additional modifiable contributors. 3

Differential Diagnoses

2. Pulmonary Disease (COPD exacerbation or pneumonia)
Dyspnea and cough could suggest primary pulmonary pathology. 3 However, patient lacks fever, productive cough, wheezing, or significant smoking history to support COPD. The presence of orthopnea, PND, JVD, S3 gallop, hepatomegaly, and bilateral dependent edema strongly favor cardiac rather than pulmonary etiology. 3 Bibasilar crackles with pleural effusions are more consistent with pulmonary congestion from heart failure. 3

3. Chronic Kidney Disease with Volume Overload
Renal failure can cause edema and dyspnea from fluid retention. 3 However, the constellation of cardiac findings (S3, displaced PMI, JVD, hepatojugular reflux) indicates primary cardiac dysfunction. 3 Renal function testing will help differentiate, but the clinical presentation is dominated by cardiac signs. 3

4. Cirrhosis with Portal Hypertension
Hepatomegaly, ascites, and peripheral edema could suggest liver disease. 3 However, patient lacks stigmata of chronic liver disease (jaundice, spider angiomata, palmar erythema), has no history of alcohol abuse or hepatitis, and the hepatomegaly is more consistent with hepatic congestion from right heart failure. 3 The presence of JVD and positive hepatojugular reflux confirms cardiac etiology. 3

5. Pulmonary Embolism
Acute dyspnea and tachypnea could suggest PE. 3 However, the gradual onset over weeks, absence of pleuritic chest pain or hemoptysis, and presence of chronic congestive signs (orthopnea, PND, chronic edema) make PE unlikely. 3 The clinical picture is more consistent with progressive heart failure decompensation. 3

6. Severe Anemia or Thyroid Disorder (High Output Heart Failure)
Fatigue and dyspnea could indicate anemia or thyrotoxicosis causing high-output failure. 3 However, patient lacks tachycardia >120 bpm, warm peripheries, or other signs of high-output state. 3 Laboratory testing will rule out these conditions, but the presentation favors low-output heart failure. 3

---

PLAN

Diagnostic Work-Up

Immediate/Urgent Diagnostics (to be obtained today):

1. 12-lead Electrocardiogram (ECG) - To assess for acute ischemia, prior myocardial infarction, left ventricular hypertrophy, arrhythmias, and conduction abnormalities. 4

2. Chest X-ray (PA and lateral) - To evaluate for cardiomegaly, pulmonary congestion, pleural effusions, and rule out pneumonia. 3

3. B-type Natriuretic Peptide (BNP) or NT-proBNP - Elevated levels support heart failure diagnosis and correlate with severity; essential component of Universal Definition of HF. 3

4. Complete Blood Count (CBC) - To rule out anemia as contributing factor or alternative diagnosis. 3

5. Comprehensive Metabolic Panel (CMP) - Including sodium, potassium, chloride, bicarbonate, BUN, creatinine, glucose; to assess renal function, electrolytes, and volume status before initiating therapy. 3

6. Liver Function Tests - To assess hepatic congestion and rule out primary liver disease. 3

7. Thyroid Stimulating Hormone (TSH) - To rule out thyroid dysfunction as contributing factor. 3

8. Lipid Panel - To assess cardiovascular risk and optimize statin therapy. 4

9. Hemoglobin A1c - To assess diabetes control. 4

10. Troponin I or T - To rule out acute coronary syndrome as precipitant. 4

Diagnostic Studies (to be scheduled within 1 week):

1. Transthoracic Echocardiogram with Doppler - Essential to assess left ventricular ejection fraction, wall motion abnormalities, valvular function, chamber sizes, diastolic function, and estimate pulmonary artery pressures. 3, 7 This is mandatory for diagnosis per Universal Definition of HF. 3

Additional Diagnostics (if indicated based on initial results):

1. Coronary angiography or stress testing - If troponin elevated or ECG shows new ischemic changes, given history of CAD. 4

Immediate Management (Acute Decompensation - Outpatient vs. Inpatient Decision)

Given the patient's presentation with NYHA Class III-IV symptoms, acute decompensation with significant volume overload, elevated JVP, bibasilar crackles, hepatomegaly, and SpO2 93% on room air, hospitalization is warranted for close monitoring and aggressive diuresis. 3

If patient were stable enough for outpatient management (which is NOT the case here), the following would apply:

Pharmacological Treatment Plan (Evidence-Based Quadruple Therapy for HFrEF)

The cornerstone of chronic heart failure management includes ACE inhibitors, beta-blockers, mineralocorticoid receptor antagonists, and SGLT2 inhibitors (quadruple therapy). 6 However, given acute decompensation, initiation must be carefully sequenced.

Phase 1: Acute Diuresis and Stabilization (Hospital/First 48-72 hours)

1. Loop Diuretic Therapy - Furosemide IV

   • Rationale: Essential for symptomatic relief when fluid overload presents as pulmonary congestion and peripheral edema, resulting in rapid improvement of dyspnea. 3
   • Dosing: Initiate furosemide 40 mg IV bolus, then continuous infusion or twice-daily IV dosing based on response. 3 In patients on chronic oral diuretics, IV dose should be at least equivalent to oral dose. 8
   • Monitoring: Daily weights, strict intake/output monitoring, assess for symptomatic improvement in dyspnea and reduction in edema. 3, 6 Monitor electrolytes (especially potassium) and renal function daily during aggressive diuresis. 3
   • Target: Net negative fluid balance of 1-2 liters daily until euvolemia achieved (resolution of JVD, crackles, edema). 3

2. Discontinue NSAID (Ibuprofen) Immediately

   • Critical intervention: NSAIDs cause sodium retention, increase blood pressure, reduce diuretic efficacy, and worsen heart failure. 3, 6 This is likely a major contributor to her decompensation.
   • Alternative: Acetaminophen 650 mg every 6 hours as needed for knee pain (maximum 3000 mg daily). Consider referral to orthopedics for non-pharmacological interventions.

3. Continue Current ACE Inhibitor (Lisinopril)

   • Patient is already on lisinopril 10 mg daily, which should be continued during hospitalization unless hemodynamically unstable. 8, 6 Do not discontinue ACE inhibitors reflexively during acute decompensation. 6

4. Optimize Blood Pressure Control

   • Target BP <130/80 mmHg per ACC guidelines for HFpEF, applicable to HFrEF as well. 7

Phase 2: Initiation and Titration of Guideline-Directed Medical Therapy (Post-Stabilization)

Once patient is euvolemic and hemodynamically stable (typically 3-5 days post-admission):

1. ACE Inhibitor Optimization

   • Current: Lisinopril 10 mg daily (suboptimal dose)
   • Target dose: Lisinopril 40 mg daily (proven effective in large trials). 3
   • Titration protocol: 3, 6
     • Reduce loop diuretic dose 24 hours before each ACE inhibitor dose increase to minimize hypotension risk. 3
     • Increase lisinopril to 20 mg daily, monitor for 1-2 weeks
     • If tolerated, increase to 30 mg daily, monitor for 1-2 weeks
     • If tolerated, increase to target 40 mg daily
   • Monitoring: Check blood pressure, serum creatinine, BUN, eGFR, and electrolytes (sodium, potassium) 1-2 weeks after each dose increment, then at 3 months, then every 6 months. 3, 6
   • Precautions: Avoid potassium-sparing diuretics during ACE inhibitor titration. 3 If serum creatinine increases >30% or potassium >5.5 mEq/L, hold dose increase and recheck in 1 week. If renal function deteriorates substantially, consider stopping. 3
   • Alternative if ACE inhibitor not tolerated: Angiotensin receptor blocker (ARB) such as valsartan or losartan. 3 However, ARBs may not be as effective as ACE inhibitors for mortality reduction. 3

2. Beta-Blocker Initiation

   • Indication: Mandatory for all stable patients with HFrEF already on ACE inhibitors and diuretics; reduces mortality, hospitalizations, and slows disease progression. 3, 6
   • Agent: Carvedilol, metoprolol succinate (extended-release), or bisoprolol (evidence-based agents). 3
   • Initiation timing: Start once patient is euvolemic and on stable diuretic dose, typically 3-5 days post-admission or at hospital discharge. 6
   • Dosing example (Carvedilol):
     • Start: Carvedilol 3.125 mg twice daily
     • Target: Carvedilol 25 mg twice daily (for patients <85 kg) or 50 mg twice daily (for patients ≥85 kg)
     • Titration: Double dose every 2 weeks as tolerated
   • Monitoring: Heart rate (target 60-70 bpm), blood pressure, signs of worsening heart failure. 6
   • Precautions: Exclude sick sinus syndrome, high-grade AV block, or severe obstructive lung disease before initiation. 6 Continue beta-blockers during acute decompensations unless patient is hemodynamically unstable. 8, 6

3. Mineralocorticoid Receptor Antagonist (Spironolactone)

   • Indication: Recommended in advanced heart failure (NYHA class III-IV) in addition to ACE inhibitors and diuretics to improve survival and reduce morbidity. 3, 6
   • Dosing: 3, 6
     • Start: Spironolactone 12.5 mg daily for 1 week
     • Check serum potassium and creatinine after 5-7 days
     • If K+ <5.0 mEq/L and creatinine stable, increase to 25 mg daily
     • Target: 25-50 mg daily (maximum 50 mg daily per guidelines)
     • Recheck potassium and creatinine every 5-7 days until stable, then monthly for 3 months, then every 3 months
   • Contraindications: Serum potassium >5.0 mEq/L, serum creatinine >2.5 mg/dL, or eGFR <30 mL/min. 3
   • Monitoring: Vigilant monitoring for hyperkalemia is essential, especially in elderly patients and when combined with ACE inhibitors. 6

4. SGLT2 Inhibitor (if not contraindicated)

   • Indication: Emerging as fourth pillar of HFrEF therapy with mortality and hospitalization benefits, also beneficial for diabetes control. (Note: Not extensively covered in provided guidelines but part of contemporary quadruple therapy)
   • Agent: Dapagliflozin 10 mg daily or empagliflozin 10 mg daily
   • Monitoring: Volume status, renal function, genital mycotic infections

5. Cardiac Glycoside (Digoxin) - Consider if Symptomatic Despite Optimal Therapy

   • Indication: May be added for persistent symptoms in patients already on ACE inhibitor, beta-blocker, and diuretic. 3 Improves symptoms but does not reduce mortality. 3
   • Dosing: Low-dose digoxin 0.125 mg daily (elderly patients are more prone to toxicity). 6
   • Monitoring: Serum digoxin level (target 0.5-0.9 ng/mL), renal function, potassium, heart rate.

6. Antiplatelet Therapy

   • Continue: Aspirin 81 mg daily given history of coronary artery disease. 4

7. Statin Therapy

   • Continue: Atorvastatin 20 mg daily; consider increasing to 40-80 mg daily based on lipid panel results and cardiovascular risk. 4

8. Diabetes Management

   • Continue: Metformin 1000 mg twice daily (monitor renal function closely; discontinue if eGFR <30 mL/min)
   • Optimize: Target HbA1c <7% to reduce cardiovascular risk. 4

Non-Pharmacological Management

Patient Education (Critical for Self-Management): 3, 6

1. Disease Understanding:

   • Explain that heart failure means the heart muscle is weakened and cannot pump blood effectively to meet the body's needs. 3
   • Discuss that fluid accumulates in lungs (causing shortness of breath) and body tissues (causing swelling). 3
   • Emphasize that heart failure is a chronic condition requiring lifelong management but can be controlled with medications and lifestyle changes. 3

2. Symptom Recognition and When to Seek Help: 3, 6

   • Call provider immediately if:
     • Sudden weight gain >2-3 pounds in 1 day or >5 pounds in 1 week 3, 6
     • Increased shortness of breath, especially at rest or lying flat 3
     • New or worsening swelling of ankles, legs, or abdomen 3
     • Persistent cough or coughing up pink, frothy sputum 3
     • Increased fatigue or inability to perform usual activities 3
     • Dizziness, confusion, or fainting 2
     • Chest pain or palpitations 3

3. Daily Self-Weighing: 3, 6

   • Weigh every morning after urination, before breakfast, in similar clothing
   • Record weight in log
   • If weight increases >2-3 pounds in 1 day or >5 pounds in 1 week, increase diuretic dose as prescribed and call provider 3, 6

4. Medication Adherence: 3, 6

   • Emphasize critical importance of taking all medications as prescribed, even when feeling better
   • Explain rationale for each medication (ACE inhibitor protects heart and kidneys, beta-blocker slows heart rate and improves pumping, diuretic removes excess fluid, etc.) 3
   • Discuss common side effects and when to report them
   • Provide written medication schedule

Dietary Modifications: 3, 6

1. Sodium Restriction:

   • Target: <2000 mg (2 grams) sodium per day; in severe heart failure <1500 mg daily 3
   • Avoid adding salt to food, avoid processed foods, canned soups, deli meats, fast food, restaurant meals
   • Provide written list of high-sodium foods to avoid and low-sodium alternatives
   • Refer to dietitian for individualized meal planning

2. Fluid Restriction:

   • Target: 1.5-2 liters (approximately 6-8 cups) total fluid per day in severe heart failure 3
   • Include all liquids (water, coffee, tea, soup, ice cream, etc.)
   • Use smaller cups/glasses to help monitor intake

3. Alcohol Limitation:

   • Recommendation: Avoid excessive alcohol; limit to ≤1 drink per day for women 3
   • Explain that alcohol can weaken heart muscle and interact with medications 8

Lifestyle Modifications: 3, 6

1. Physical Activity:

   • Recommendation: Encourage regular low-to-moderate intensity physical activity in stable patients to prevent muscle deconditioning. 3, 6
   • Rest is NOT encouraged in stable conditions. 3
   • Start with short walks (5-10 minutes) and gradually increase duration as tolerated
   • Structured cardiac rehabilitation program is appropriate for NYHA class II-III patients. 3, 6
   • Stop activity if experiencing chest pain, severe shortness of breath, dizziness, or palpitations

2. Smoking Cessation:

   • Status: Patient quit 10 years ago - reinforce importance of continued abstinence 3

3. Weight Management:

   • Target BMI <30; current BMI 34
   • Weight loss will reduce cardiac workload and improve symptoms
   • Refer to dietitian for structured weight loss plan

4. Stress Management:

   • Recommend stress reduction techniques (meditation, deep breathing, support groups)
   • Consider referral to behavioral health if anxiety worsens

Travel Considerations: 3, 6

• Advise about potential problems with long flights (risk of DVT, difficulty with fluid/sodium restriction), high altitudes (reduced oxygen), and hot humid climates (increased fluid loss) while on diuretics and vasodilators 3, 6

Device Therapy and Advanced Interventions (Future Considerations)

1. Implantable Cardioverter-Defibrillator (ICD):

   • Consider if LVEF remains ≤35% despite 3 months of optimal medical therapy, for primary prevention of sudden cardiac death. 3
   • Requires echocardiogram results and reassessment after medical optimization.

2. Cardiac Resynchronization Therapy (CRT/Biventricular Pacing):

   • Consider if LVEF ≤35%, QRS duration ≥120 ms, and NYHA class II-IV despite optimal medical therapy. 3
   • May improve symptoms and submaximal exercise capacity. 3

3. Coronary Revascularization:

   • Given history of CAD, reassess need for revascularization if echocardiogram shows significant ischemic cardiomyopathy or if symptoms suggest ongoing ischemia. 4
   • Optimal revascularization strategy requires careful assessment of individual risk/benefit profile. 4

4. Heart Transplantation Evaluation:

   • If patient persists in NYHA class IV despite optimal medical therapy, consider referral for transplant evaluation. 3
   • Heart transplantation significantly increases survival, exercise capacity, and quality of life in end-stage heart failure. 3

Follow-Up Plan

Immediate Follow-Up (Post-Hospitalization):

• First outpatient visit within 7-10 days of hospital discharge 6
• Assess volume status, medication tolerance, vital signs, weight
• Review home weight log and symptom diary
• Reinforce education and answer questions

Short-Term Follow-Up:

• Weekly visits for first month to monitor diuretic response, medication titration, and clinical stability
• Check blood pressure, heart rate, weight, volume status at each visit
• Laboratory monitoring: BMP (creatinine, BUN, electrolytes) 1-2 weeks after each medication dose change 3, 6

Long-Term Follow-Up:

• Monthly visits for 3 months, then every 3 months once stable on optimal medical therapy
• Laboratory monitoring: BMP every 3 months, then every 6 months once stable 3, 6
• Annual echocardiogram to reassess LVEF and cardiac function
• Annual HbA1c, lipid panel, TSH

Multidisciplinary Heart Failure Management Program:

• Enroll patient in multidisciplinary heart failure clinic to reduce rehospitalization rates and mortality. 8, 6
• Team includes cardiologist, heart failure nurse, dietitian, pharmacist, social worker, and physical therapist
• Provides intensive education, medication management, dietary counseling, and close monitoring

Specialist Referrals:

• Cardiology: Urgent referral for echocardiogram interpretation, medication optimization, and consideration for advanced therapies
• Dietitian: For individualized sodium-restricted, heart-healthy meal planning and weight management
• Cardiac Rehabilitation: For structured, supervised exercise program
• Orthopedics: For non-pharmacological management of knee osteoarthritis (physical therapy, injections, possible surgery) to eliminate need for NSAIDs
• Endocrinology: If diabetes remains poorly controlled despite optimization

Common Pitfalls to Avoid

1. Do NOT discontinue ACE inhibitors or beta-blockers during acute decompensations unless true hemodynamic instability (cardiogenic shock) is present. 8, 6 These medications should be continued during hospitalization.

2. Avoid premature reduction or discontinuation of diuretics, which can leave patients congested and increase readmission risk. 8, 6

3. Do NOT stop diuretics solely because of mild worsening renal function; modest rises in BUN/creatinine are often tolerated and preferable to persistent congestion. 6

4. Refrain from excessive diuresis before initiating or up-titrating ACE inhibitors, as this raises the risk of hypotension and acute kidney injury. 3, 6

5. Monitor hyperkalemia vigilantly, especially when combining mineralocorticoid receptor antagonists with ACE inhibitors. 6 Check potassium frequently during titration.

6. Thiazide diuretics should not be used when eGFR <30 mL/min unless combined with a loop diuretic for synergistic effect. 3, 6

7. NSAIDs and COX-2 inhibitors must be avoided as they increase hyperkalemia risk, cause sodium retention, and exacerbate heart failure. 3, 6

8. Recognize that symptom relief may be prioritized over life-prolongation in elderly patients; treatment goals should be individualized. 6 However, this patient at age 62 is appropriate for aggressive guideline-directed medical therapy.

9. Do NOT rely on dyspnea alone to assess functional class; profound fatigue is more reliable as an indicator of worsening heart failure. 2

10. Failure to recognize the absolute requirement for complete NSAID cessation is a common and dangerous pitfall that will lead to progressive heart failure. 3, 8, 6

---

Prognosis Discussion:

Heart failure is a serious chronic condition with 50% 5-year mortality. 5 However, with strict adherence to guideline-directed medical therapy, lifestyle modifications (especially sodium restriction and NSAID avoidance), and close follow-up in a multidisciplinary heart failure program, many patients experience significant improvement in symptoms, functional capacity, and survival. 8, 6 The patient's prognosis will depend heavily on her LVEF (to be determined by echocardiogram), adherence to treatment, and elimination of exacerbating factors (NSAIDs, high sodium diet). 5, 9